[1] |
Harris JC. Lesch-Nyhan syndrome and its variants: examining the behavioral and neurocognitive phenotype[J]. Curr Opin Psychiatry, 2018, 31(2): 96-102.
doi: 10.1097/YCO.0000000000000388
|
[2] |
Nguyen KV, Nyhan WL. Mutation in the Human HPRT1 Gene and the Lesch-Nyhan Syndrome[J]. Nucleosides Nucleotides Nucleic Acids, 2016, 35(8): 426-433.
doi: 10.1080/15257770.2015.1098660
pmid: 27379977
|
[3] |
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5): 405-424.
doi: 10.1038/gim.2015.30
pmid: 25741868
|
[4] |
Cho JH, Choi JH, Sun HH, et al. Phenotypic and molecular spectrum of Korean patients with Lesch-Nyhan syndrome and attenuated clinical variants[J]. Metab Brain Dis, 2019, 34(5): 1335-1340.
doi: 10.1007/s11011-019-00441-0
|
[5] |
Fu R, Ceballos-Picot I, Torres RJ, et al. Genotype-phenotype correlations in neurogenetics: Lesch-Nyhan disease as a model disorder[J]. Brain, 2014, 137: 1282-1303.
doi: 10.1093/brain/awt202
|
[6] |
田小娟, 丁昌红, 代丽芳, 等. HPRT1基因突变致Lesch-Nyhan综合征1例临床特点及基因分析[J]. 中华实用儿科临床杂志, 2019, 34(18): 1424-1426.
|
[7] |
Ambarsari CG, Cahyadi D, Sari L, et al. Late diagnosis of Lesch-Nyhan disease complicated with end-stage renal disease and tophi burst: a case report[J]. Ren Fail, 2020, 42(1): 113-121.
doi: 10.1080/0886022X.2020.1713805
pmid: 31985336
|
[8] |
Bell S, Kolobova I, Crapper L, et al. Lesch-Nyhan Syndrome: Models, Theories, and Therapies[J]. Mol Syndromol, 2016, 7(6): 302-311.
doi: 10.1159/000449296
|
[9] |
Mishima E, Mori T, Nakajima Y, et al. HPRT-related hyperuricemia with a novel p.V35M mutation in HPRT1 presenting familial juvenile gout[J]. CEN Case Rep, 2020, 9(3): 210-214.
doi: 10.1007/s13730-020-00459-9
|
[10] |
Cakmakli HF, Torres RJ, Menendez A, et al. Macrocytic anemia in Lesch-Nyhan disease and its variants[J]. Genet Med, 2019, 21(2): 353-360.
doi: 10.1038/s41436-018-0053-1
pmid: 29875418
|
[11] |
Salhotra R, Sharma C, Tyagi A, et al. An unanticipated difficult airway in Lesch-Nyhan syndrome[J]. J Anaesthesiol Clin Pharmacol, 2012, 28(2): 239-241.
doi: 10.4103/0970-9185.94909
pmid: 22557752
|
[12] |
Torres RJ, Puig JG, Jinnah HA. Update on the phenotypic spectrum of lesch-nyhan disease and its attenuated variants[J]. Curr Rheumatol Rep, 2012, 14(2): 189-194.
doi: 10.1007/s11926-011-0231-5
pmid: 22198833
|
[13] |
中华医学会内分泌学分会. 中国高尿酸血症与痛风诊疗指南(2019)[J]. 中华内分泌代谢杂志, 2020, 36(1): 1-13.
|
[14] |
Jacomelli G, Baldini E, Mugnaini C, et al. Inhibiting PNP for the therapy of hyperuricemia in Lesch-Nyhan disease: Preliminary in vitro studies with analogues of immucillin[J]. J Inherit Metab Dis, 2019, 42(1): 178-185.
doi: 10.1002/jimd.12039
|
[15] |
Pozzi M, Piccinini L, Gallo M, et al. Treatment of motor and behavioural symptoms in three Lesch-Nyhan patients with intrathecal baclofen[J]. Orphanet J Rare Dis, 2014, 9(1): 208.
doi: 10.1186/s13023-014-0208-3
|
[16] |
Khasnavis T, Torres RJ, Sommerfeld B, et al. A double-blind, placebo-controlled, crossover trial of the selective dopamine D1 receptor antagonist ecopipam in patients with Lesch-Nyhan disease[J]. Mol Genet Metab, 2016, 118(3):160-166.
doi: 10.1016/j.ymgme.2016.04.012
pmid: 27179999
|
[17] |
Chen BC, Balasubramaniam S, McGown IN, et al. Treatment of Lesch-Nyhan disease with S-adeno-sylmethionine: experience with five young Malaysians, including a girl[J]. Brain Dev, 2014, 36(7): 593-600.
doi: 10.1016/j.braindev.2013.08.013
|
[18] |
Tambirajoo K, Furlanetti L, Hasegawa H, et al. Deep brain stimulation of the internal pallidum in Lesch-Nyhan syndrome: clinical outcomes and connectivity analysis[J]. Neuromodulation, 2020, 24(2):380-391.
doi: 10.1111/ner.13217
|
[19] |
Gilbert C, Sauer M, Cheng J. Reduction of self-mutilating behavior and improved oromotor function in a patient with Lesch-Nyhan syndrome following botulinum toxin injection: A case report[J]. J Pediatr Rehabil Med, 2021, 14(1): 133-136.
doi: 10.3233/PRM-200729
|